Replies to post #254844 on Biotech Values

[alertmeipp]

So there are still lot of interests in this field but still no deal for VKTX - wonder why

[DewDiligence]

LXRX—(+82%)—inks NVO collaboration with $75M up-front/near-term cash and $1B total biobucks:

https://www.globenewswire.com/news-release/2025/03/28/3051285/0/en/Lexicon-Pharmaceuticals-Announces-Exclusive-License-Agreement-with-Novo-Nordisk-for-LX9851.html

Lexicon Pharmaceuticals, Inc…today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S for LX9851, a first-in-class, oral non-incretin development candidate in obesity and associated metabolic disorders. Under the terms of the agreement, Novo Nordisk obtains an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications.

This is NVO's second in-licensing deal this week (#msg-175967769).

[DewDiligence]

NVO CCO leaves for no stated reason:

https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisks-head-commercial-strategy-steps-down-2025-04-03/

[DewDiligence]

NOVO reports phase-2 data_on “triple G” candidate, UBT251:

https://www.fiercebiotech.com/biotech/novo-nordisks-triple-g-candidate-drives-20-weight-loss-phase-2-china

https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916503

https://doc.irasia.com/listco/hk/unitedlab/announcement/a260224.pdf

NVO licensed the ex-China commercial rights to UB225151 from China’s United Laboratories one year ago (#msg-175967769). UBT251 hits the same three targets (GLP-1, GIP, and glucoagon) as LLY’s retatrutide. NVO and United’s PRs today have topline data from a phase-2 trial of UBT251 in China. The full dataset will be presented at an unspecified medical conference.

NVO has on ongoing phase-2 trial of UBT251 in North America.